4 stories mentioning HKG:6955Updated 41d ago
Every FINWIRES story that references HKG:6955, newest first.
Shandong Boan Biotechnology (HKG:6955) obtained approval for a phase II clinical trial of its anti-CD25 antibody BA1106 from China's National Medical Products Administration.The drug is being tested in combination with a PD-1 inhibitor BA1104 as first- or second-line regimen for non-small cell lung cancer, according to a Thursday filing.
Shandong Boan Biotechnology (HKG:6955) licensed BA5101 to a partner in the U.S., according to a Thursday filing with the Hong Kong bourse.The firm's partner will be responsible for commercializing the diabetes treatment in the U.S., including the submission of the biologics license application and sales.BA5101, also known as dulaglutide, is a biosimilar version of Trulicity.The company said it is eligible for an upfront payment, as well as milestone payouts and sales commissions.
Shandong Boan Biotechnology (HKG:6955) announced plans to buy back up to HK$200 million of its shares, according to a Wednesday filing with the Hong Kong bourse.The pharmaceutical company's shares gained over 3% in morning trade Thursday.
Shandong Boan Biotechnology (HKG:6955) said Chinese regulators had accepted the firm's application to conduct a phase 2 trial of BA1106 in lung cancer for review, according to a Hong Kong bourse filing Sunday.Shares of the pharmaceutical company gained over 2% in morning trade Monday.The company is seeking approval to study the drug in combination with another of its medicine, BA1104, as a first-line or second-line treatment of non-small cell lung cancer.
